EGFR and neoplasm: The results showed that once-daily dosing of deguelin significantly inhibited the tumor growth in EGFR-activating mutant-harbored cells, including HCC827 (Fig. 7a, b), H3255 (Fig. 7c, d), and H1975 (Fig. 7e, f) xenograft tumors (Supplementary Fig. 5a–c).